Healthy
Conditions
Brief summary
This is a phase1, single center, double-blind, placebo control, randomized study and consisted of single dosing(period 1) and multiple dosing(period 2). In this clinical trial, safety and local tolerability are evaluated for 7 days after single dosing of the investigational product. If multiple dosing is judged to be acceptable as a result of single dosing evaluation (safety and local tolerability evaluation including ophthalmic examination), multiple dosing starts from Day 8(7 days after the single dosing) for 14 days. Safety and local tolerability, including ophthalmic symptom assessment, should be evaluated during the multiple dosing period.
Interventions
DRUGSJP002
1. Period 1 (single dose) * Day1: Placebo, Topical administered one drop to each eye (Once a day) * Day2: SJP002, Topical administered one drops to each eye (Once a day) * Day3: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\]) 2. Period 2 (multiple dose) - Day10\ Day23: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])
DRUGPlacebo
1. Period 1 (single dose) * Day1: Placebo, Topical administered one drop to each eye (Once a day) * Day2: Placebo, Topical administered one drops to each eye (Once a day) * Day3 Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\]) 2. Period 2 (multiple dose) - Day10\ Day23: Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])
Sponsors
Samjin Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
20 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subject who voluntarily agrees to participate in this study and has given a written informed consent, after fully understanding the detailed explanation of this study 2. 20 years to 50 years (Healthy male Korean)
Exclusion criteria
1. Subject with a disease history of any clinically significant condition as below. \- Liver, Kidney, nervous system, immune system, respiratory system, endocrine system, tumor, cardiovascular disease or mental illness (mood disorder or obsessive-compulsive disorder etc.) etc. 2. Subject with a history of clinically significant hypersensitivity or hypersensitivity reactions to drugs (aspirin, antibiotics, etc.) 3. Subject with a disease history of any ophthalmic condition as below * History of or suspected symptoms or signs of vision problems, including keratitis, uveitis, retinitis, dry eye syndrome, and strabismus. * Corrected eyesight measured at screening is 20/40 or less * Those who have previously had ophthalmic surgery. (Exceptional case: in the case of having ophthalmic laser surgery before 6 months from the screening) * Those who have experienced side effects after wearing contact lenses, those who have worn contact lenses within the last month, or those who cannot ban wearing contact lens during the clinical trial * Abnormal findings in other ophthalmic examinations 4. Subject with a history of drug abuse or who is positive for drugs of abuse in urine tests at screening 5. Subject who received any drugs such as * Prescription drug or herbal medicine within 14 days prior to the first administration of the investigational products * Over the counter (OTC) or vitamin within 7 days prior to the first administration of the investigational products 6. Subject who received other investigational products within 90 days prior to the first administration of the investigational products 7. Subject who have donated whole blood within 60 days prior to the first administration of the investigational products, or donated component blood or have received blood transfusion within 30 days prior to the first administration of the investigational products 8. Subject who continuously drink alcohol (more than 21 units/week, 1 unit = 10 g of pure alcohol) or cannot abstain from alcohol during the study period 9. Subject who smoked more than 10 cigarettes a day on average in the last 90 days, and who cannot quit smoking during hospitalization 10. Man of reproductive potential not willing to use contraceptive measures during the study period 11. Subject not eligible for study participation in the opinion of the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment Emergent Adverse Event(TEAE) | Day 1(administration) to approximately Day 37(Post study visit) | Safety/Tolerability Assessment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measure the Area Under the plasma concentration versus time Curve from the first observed to last(AUClast) of SJP002 | Period 1: Day2(predose and 0.5~24 hours postdose) | Investigate the pharmacokinetic parameters by collecting blood before and during administration of the investigational product |
| Measure the Area Under the plasma concentration versus time Curve from the first sampled data extrapolated to infinity(AUCinf) of SJP002 | Period 1: Day2(predose and 0.5~24 hours postdose) | Investigate the pharmacokinetic parameters by collecting blood before and during administration of the investigational product |
| Measure the Time to peak drug concentration(Tmax) of SJP002 | Period 1: Day2(predose and 0.5~24 hours postdose) | Investigate the pharmacokinetic parameters by collecting blood before and during administration of the investigational product. |
| Measure the Half Life(t1/2) of SJP002 | Period 1: Day2(predose and 0.5~24 hours postdose) | Investigate the pharmacokinetic parameters by collecting blood before and during administration of the investigational product. |
| Measure the Peak Plasma Concentration (Cmax) of SJP002 | Period 1: Day2(predose and 0.5~24 hours postdose) | Investigate the pharmacokinetic parameters by collecting blood before and during administration of the investigational product. |
| Measure the Area Under the plasma concentration-time Curve over a dosing interval at steady state(AUCtau,ss) of SJP002 | Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose) | Investigate the pharmacokinetic parameters by collecting blood before and during administration of the investigational product. |
| Measure the Time to peak drug concentration at steady state(Tmax,ss) of SJP002 | Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose) | Investigate the pharmacokinetic parameters by collecting blood before and during administration of the investigational product. |
| Measure the Half Life at steady state(T1/2,ss) of SJP002 | Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose) | Investigate the pharmacokinetic parameters by collecting blood before and during administration of the investigational product. |
| Measure the Peak Plasma Concentration Accumulation Ratio (RA,Cmax) of SJP002 | Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose) | Investigate the pharmacokinetic parameters by collecting blood before and during administration of the investigational product. |
| Measure the Trough Drug Concentration at steady state(Cmin,ss) of SJP002 | Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose) | Investigate the pharmacokinetic parameters by collecting blood before and during administration of the investigational product. |
Countries
South Korea
Outcome results
None listed